Altogether, the study highlights peri-puberty as a critical and potentially actionable window for interventions targeting long-term cardiovascular health
Survodutide (SYNCHRONIZE): Approximately 19% body weight loss at the highest dose in Phase 3
secondary IR cross-reactivity Key downstream pathways / PI3K-Akt-mTOR and RAS-MAPK-ERK IGF-1 DES comparison / DES is 6-aa truncated, 10x higher potency but even shorter half-life (~20-30 min) Regulatory status / Not FDA-approved for any indication
The clinics segment is expected to grow at a rapid pace in the coming years due to their increasing role in providing specialized, accessible, and personalized weight management services
Recent research suggests that there are effective treatments available to reduce the symptoms of neuropathy and even reverse nerve damage
Its generally considered safe for short-term use, and a limited number of small studies in specific populations have shown that doses of around 30 grams per day may aid weight loss
